Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.52 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578230 | 0.96 | HRH3 (0.55) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL3582655 | 0.96 | HRH3 (0.55) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL3581861 | 0.96 | HRH3 (0.55) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL3581307 | 0.92 | HRH3 (0.55) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL3577368 | 0.91 | HRH3 (0.54) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL3584637 | 0.90 | HRH3 (0.57) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL3586737 | 0.89 | HRH3 (0.53) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL3589140 | 0.89 | HRH3 (0.54) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL3584805 | 0.87 | HRH3 (0.52) | HRH3KCNH2 | |
| SCHEMBL3579676 | 0.87 | HRH3 (0.55) | HRH3HTR3AKCNH2CHRM2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | claimed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | claimed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | HRH3 1/4885HTR3A 125/4885KCNH2 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.